Abatacept: The evidence for its place in the treatment of rheumatoid arthritis

Core Evidence

Volumn 2, Issue 3, 2008, Pages 163-172

  Köller, Marcus D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Abatacept; Biologics; Disease modifying antirheumatic drugs; Rheumatoid arthritis

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HUMAN; INFECTION RISK; JOINT DESTRUCTION; LUNG CANCER; LYMPHOMA; NONHUMAN; QUALITY OF LIFE; RADIODIAGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION;

EID: 65849142845     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
2. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
3. Bristol-Myers Squibb Company. Briefing document for abatacept (BMS-188667). Biological license application 125118. Princeton, NJ: Bristol-Myers Squibb Company; September 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/ 2005-4170B1_01_01-BMS-Abatacept.pdf (accessed June 2007).
4. Dougados M, Russell A, Li T, et al. Abatacept reduces fatigue and pain severity and sleep problems through 2 years in rheumatoid arthritis patients in the AIM and ATTAIN trials. Ann Rheum Dis. 2007a;66(Suppl. II):429. Abstract SAT0005.
5. Dougados M, Emery P, Westhovens R, et al. Abatacept provides increasing improvements in clinical measures of disease activity over time: Results from the AIM trial. Ann Rheum Dis. 2007b;66(Suppl. II):429. Abstract SAT0004.
6. Dougados M, Keiserman M, Codding C, et al. Efficacy of abatacept or infliximab treatment in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a 1-year double-blind, randomized, placebo-controlled trial. Ann Rheum Dis. 2007c;66(Suppl. II):88. Abstract OP0118.
7. Doyle JJ. Economic and quality-of-life impact of rheumatoid arthritis. Manag Care. 2001;10:15-18.
8. Dumont FJ. Technology evaluation: Abatacept, Bristol-Myers Squibb. Curr Opin Mol Ther. 2004;6:318-330.
9. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-2581.
10. Emery P, Kosinski M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol. 2006;33:681-689
11. FDA (Food and Drug Administration). CDER new molecular entity (NME) drug and new biologic approvals in calendar year 2005. December 31, 2005. Available at: http://www.fda.gov/cder/rdmt/InternetNME05.htm (accessed June 2007).
12. Felson DT, Anderson JJ, Boers M, et al; American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-735.
13. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:269-281.
14. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443-1450.
15. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353:1114-1123.
16. Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol. 2004;16:212-217.
17. Hassett AL, Maclean JR, Stuart MR, et al. An observational evaluation of psychological well-being in rheumatoid arthritis in the ATTAIN trial for abatacept. Ann Rheum Dis. 2007;66(Suppl. II):440. Abstract SAT0037-AHP.
18. Keystone EC, Kavanaugh A. What to do with TNF failures. Expert Opin Drug Saf. 2005;4:149-155.
19. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest. 1995;96:987-993.
20. Köller MD. Targeted therapy in rheumatoid arthritis. Wien Med Wochenschr. 2006;156:53-60.
21. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907-1915.
22. Kremer JM. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis. Rheum Dis Clin North Am. 2004;30:381-391, viii.
23. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:2263-2271.
24. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann Intern Med. 2006;144:865-876.
25. Lassere M. Pooled metaanalysis of radiographic progression: Comparison of Sharp and Larsen methods. J Rheumatol. 2000;27:269-275.
26. Mikuls TR, Saag KG. Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:283-303.
27. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002;46:1470-1479.
28. National PBM (Pharmacy Benefits Management Strategic Healthcare Group). Abatacept (Orencia®) drug monograph. March 2006. Available at: http://www.pbm.va.gov/monograph/Abatacept,%20Monograph.pdf (accessed June 2007).
29. NICE (National Institute for Health and Clinical Excellence). Final appraisal determination: Abatacept in rheumatoid arthritis. London: NICE; 2007. Available at: http://guidance.nice.org.uk/ download.aspx?o=461128 (accessed November 2, 2007).
30. Pincus T, Larsen A, Brooks RH, Kaye J, Nance EP, Callahan LF. Comparison of 3 quantitative measures of hand radiographs in patients with rheumatoid arthritis: Steinbrocker stage, Kaye modified Sharp score, and Larsen score. J Rheumatol. 1997;24:2106-2112.
31. Prevoo M L, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44-48.
32. Quattrocchi E, Dallman MJ, Feldmann M. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum. 2000;43:1688-1697.
33. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: What is the evidence? Rheumatology (Oxford). 2001;40:1211-1220.
34. Quinn MA, Emery P. Are early arthritis clinics necessary? Best Pract Res Clin Rheumatol. 2005;19:1-17.
35. Redlich K, Hayer S, Ricci R, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest. 2002;110:1419-1427.
36. Russell AS, Wallenstein GV, Li T, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis. 2007;66:189-194.
37. Salliot C, Gossec L, Dougados M. Rituximab, abatacept and anakinra do not increase the risk of serious infections: A metaanalysis of published randomised controlled trials. Ann Rheum Dis. 2007;66(Suppl. II):436. Abstract SAT0027.
38. Schiff M, Keiserman M, Codding C, et al. The efficacy and safety of abatacept or infliximab in RA patients with an inadequate response to MTX: Results from a 1-year double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2006;54(Suppl.):4117. Abstract.
39. Schiff M, Pritchard C, Teng J, Bahrt K, Genovese M. The safety of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF therapy: Results from the ARRIVE trial. Ann Rheum Dis. 2007;66(Suppl. II):89. Abstract OP0121.
40. Scott DL. Pursuit of optimal outcomes in rheumatoid arthritis. Pharmacoeconomics. 2004;22(Suppl.):13-26.
41. Sfikakis PP, Via CS. Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: Implications for immunotherapy. Clin Immunol Immunopathol. 1997;83:195-198.
42. Simon TA, Smitten A, Meng M, et al. Malignancies in the rheumatoid arthritis (RA) abatacept clinical development program: An updated epidemiological assessment. Ann Rheum Dis. 2007a;66(Suppl. II):90. Abstract OP0124.
43. Simon TA, Smitten A, Meng M, et al. Serious infections in the rheumatoid arthritis abatacept clinical development program: An updated epidemiological assessment. Ann Rheum Dis. 2007b;66(Suppl. II):438. Abstract SAT0032.
44. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res Ther. 2005;7(Suppl. 2):S4-S14.
45. Smolen JS, Hayer S, Schett G, et al. Autoimmunity and rheumatoid arthritis. Autoimmun Rev. 2004;3(Suppl. 1):S23.
46. Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2005a;19:163-177.
47. Smolen JS, Redlich K, Zwerina J, Aletaha D, Steiner G, Schett G. Proinflammatory cytokines in rheumatoid arthritis: Pathogenetic and therapeutic aspects. Clin Rev Allergy Immunol. 2005b;28:239-248
48. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007 Jun 12; (Epub ahead of print).
49. Vera-Llonch M, Massarotti E, Shadick N, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Ann Rheum Dis. 2007;66(Suppl. II):277. Abstract THU0488.
50. Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2. Eur J Immunol. 1996;26:2320-2328.
51. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54:2807-2816
52. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial. Ann Rheum Dis. 2007;66:228-234.
53. Weisman MH, Durez P, Hallegua D, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006;33:2162-2166.
54. Wells G, Li T, Westhovens R, Tugwell P. Increased activity participation and its determinants in rheumatoid arthritis patients treated with abatacept. Ann Rheum Dis. 2007;66(Suppl. II):433. Abstract SAT0017.
55. Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford). 2006;45:1238-1246.
56. Zwerina J, Redlich K, Schett G, Smolen JS. Pathogenesis of rheumatoid arthritis: Targeting cytokines. Ann N Y Acad Sci. 2005;1051:716-729.